An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations

K.J. Riley, P.J. Binns, O.K. Harling, J.R. Albritton, W.S. Kiger III, A. Rezaei, K. Sköld, T. Seppalä, S. Savolainen, Iiro Auterinen, M. Marek, L. Viererbl, V.A. Nievaart, R.L. Moss

    Research output: Contribution to journalArticleScientificpeer-review

    12 Citations (Scopus)


    The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland), and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water‐filled phantom to uniformly evaluate dose specifications with an estimated precision +-2%-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10 Β uptake in tissue. Assuming a boron concentration of 15 μ gg -1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 8.9 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC), and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi‐center patient analyses.

    Original languageEnglish
    Pages (from-to)5419-5425
    Number of pages7
    JournalMedical Physics
    Issue number12
    Publication statusPublished - 2008
    MoE publication typeA1 Journal article-refereed


    • Boron neutron capture therapy
    • BNCT
    • thermal neutrons
    • dosimetry intercomparison
    • clinical trials


    Dive into the research topics of 'An international dosimetry exchange for boron neutron capture therapy. Part II: Computational dosimetry normalizations'. Together they form a unique fingerprint.

    Cite this